You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – Clinical stage drug company Relay Therapeutics said on Thursday that it has dosed the first patient in the first-in-human study of RLY-4008 in FGFR2-altered intrahepatic cholangiocarcinoma and other advanced solid tumors.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.
This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.